AskBio in the news and on the scene
AskNews™
In the Media
Events
Media Contacts
As a world-leading gene therapy company, we are continuously advancing AAV therapeutics, discovering new technology, forging new research collaborations, and adding amazing talent to our team.
AskBio To Present At The 38th Annual J.P. Morgan Healthcare Conference
AskBio today announced that Sheila Mikhail, AskBio’s Chief Executive Officer and Co-founder, has been invited to provide an overview of the company at the 38th…
AskBio Licenses Rights to Selecta Biosciences’ ImmTOR™ Immune Tolerance Platform for the Treatment of Pompe Disease
– AskBio’s AAV gene therapy combined with ImmTOR could prevent the formation of neutralizing antibodies and potentially enable re-treatment of patients with Pompe disease –
AskBio Receives “Best Venture Funding” Award from Southeast BIO
Recognition highlights $235 million investment fueling growth of company and its industry-leading gene therapy technology platform
SQZ Biotech and AskBio Announce Research Collaboration to Create Immune Tolerization Products for AAV Gene Therapies
Scientific leaders in cell and gene therapy collaborate to determine efficacy of SQZ tolerizing antigen carriers (TACs) containing AAV components to overcome patient immune responses…
Sheila Mikhail, AskBio CEO and Cofounder, Named Springboard Enterprises’ 2019 Northstar Honoree
National award recognizes outstanding entrepreneurial women who lead high-growth companies that are transforming their industries
Editas Medicine and AskBio Enter Strategic Research Collaboration to Explore In Vivo Delivery of Genome Editing Medicines to Treat Neurological Diseases
Editas and AskBio, today announced the companies have entered a strategic research collaboration to explore in vivo delivery of genome editing medicines to treat neurological…
AskBio Acquires Assets from RoverMed BioSciences, Adds Nanotechnology Precision to Delivery of AAV Gene Therapeutics
Expands AAV gene therapy platform from inside the cell for genetic disorders
Viralgen Receives cGMP Certification from European Medicines Agency
Certification confirms Viralgen’s commitment to high operational standards with the world’s most flexible and robust AAV manufacturing capability
AskBio Applauds Pfizer’s Continuing Investments in Gene Therapy
New $500 million gene therapy manufacturing facility in North Carolina further validates AskBio’s groundbreaking AAV gene therapy accomplishments
AskBio Acquires Synpromics Ltd. and Expands its Gene Therapy Technology Portfolio
Synpromics to operate as a wholly owned subsidiary; the two companies bring together pioneering technology to increase efficacy of gene therapeutics
Selecta Biosciences Combines ImmTOR™ Platform with AskBio’s IndustryLeading Gene Therapy Platform in Strategic Partnership
Development pipeline and human trials planned for repeat dosing of AAV-based gene therapies to address the unmet medical need for patients with rare and orphan…
Statement: Pfizer Phase 1b Clinical Trial Results
Pfizer reported results from a Phase 1b clinical trial of PF-06939926, its investigational gene therapy for Duchenne Muscular Dystrophy (DMD).
Newly Approved Spinal Muscular Atrophy Gene Therapy, Zolgensma®, Validates AskBio Gene Therapy Platform
AskBio continues to lead the path for gene therapy development and cost-effective manufacturing methods based on the contributions of its co-founder, Dr. Jude Samulski
AskBio Partners with TPG and Vida Ventures
Leading gene therapy company announces $235 million investment to accelerate growth
First Patient Dosed with Gene Therapy in Phase 1/2 Study of ACTUS-101 in Patients with Pompe Disease
-Initial clinical study to evaluate ACTUS-101 over 52 weeks that could improve quality of life for those who are affected with rare genetic disorder -…
Asklepios BioPharmaceutical, Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
Asklepios BioPharmaceutical,Inc. Announces Former Portfolio Company’s Preclinical Asset for Duchenne Muscular Dystrophy Has Advanced into the Clinic
Asklepios BioPharmaceutical, Inc. Launches New Portfolio Company – Actus Therapeutics, Inc.
Company will target rare genetic diseases including Pompe Disease
AskBio and Columbus Venture Partners Launch Gene Therapy Company Viralgen
New vector core facility will be located in San Sebastián, Spain
NanoCor Announces New Data on Congestive Heart Failure Gene Therapy
Up to 25 percent improvement in large animal model
Pfizer Aims To Become Industry Leader In Gene Therapy With Acquisition Of Bamboo Therapeutics, Inc.
Acquisition combines Bamboo’s gene therapy portfolio, advanced vector design, and production technologies and capabilities with Pfizer’s global scale, research, development and commercialization experience
Baxter to Acquire Chatham Therapeutics
Baxter has agreed to acquire all of Chatham’s outstanding membership interests.
Asklepios BioPharmaceutical Enters Into A Patent License Agreement With Pfizer
AskBio announced today it has entered into a patent license agreement with Pfizer, Inc.
Medtronic Makes Equity Investment in NanoCor Therapeutics, Inc.
NanoCor Therapeutics, Inc. (NanoCor) today announces an investment by Medtronic, Inc. of $3.75 million.
Triangle-based AskBio to pay up to $240M for rights to use gene therapy technology
December 19, 2019
2020: New Decade, New Disruption: Cell and Gene Therapy to Eradicate Genetic Diseases
December 3, 2019
SQZ Biotech and AskBio Collaborate to Overcome AAV Immunogenicity
December 3, 2019
R. Jude Samulski: Gene Therapy’s Guiding Force
November 9, 2019
Executive Profile: A Voyage Above and Beyond
November 2019
Cover Story: AskBio’s tumultuous ride to achieve unicorn status
July 09, 2019
Top 10 gene therapy companies in 2019
June 06, 2019
Meet Sheila Mikhail, Co-Founder of AskBio
May 28, 2019
AskBio Gets $235 Million in Gene Therapy Support
April 12, 2019
AskBio Banks $235 Million Investment To Accelerate Growth
April 11, 2019
TPG, VIDA back AskBio in $235 Million Round
April 11, 2019
AskBio’s $235 Million Financing Provides Clues to the Direction of Gene Therapy Investment
April 11, 2019
M&A Wrap
April 11, 2019
AskBio reels in $235M to ramp up gene therapy clinical trials, manufacturing
April 11, 2019
Jude Samulski Named to North Carolina Power 100
January 29, 2019
Check out the conferences and events we are attending and where we are speaking.
Alliance for Regenerative Medicine (ARM) | 2020 Cell & Gene Therapies State of the Industry
Next-Generation Gene and Cell Technologies will be on January, 13, 2020 from 9:05am – 9:50am PST
Springboard Enterprises’ 13th Annual Winners’ Circle Dinner
AskBio CEO Sheila Mikhail was recognized at Springboard Enterprises’ 13th Annual Winners’ Circle Dinner, as the 2019 Northstar honoree.
Chardan Genetic Medicines Conference
AskBio CEO Sheila Mikhail presented at the 3rd annual Chardan Genetic Medicines Conference in New York.
Cell & Gene Meeting on the Mesa
Sheila Mikhail, CEO, of AskBio presented our differentiating capabilities, technology and therapeutic pipeline.
Harvard Career Fair
Dee Commodore, Andy Holt, Candace Summerford, and Pamela Ghosh represented AskBio at the annual Harvard Career Fair presented by the GSAS Harvard Biotech Club.
National Limb Girdle Muscular Dystrophy Conference
Joy Carson and Sharon Hesterlee, joined patients, families and leading stakeholders at the first-annual National Limb Girdle Muscular Dystrophy Conference in support of the LGMD…
Parent Project Muscular Dystrophy, 25th Annual Conference
AskBio’s Jude Samulski and Sharon Hesterlee joined the 25th Parent Project Muscular Dystrophy in Orlando.
American Society of Gene & Cell Therapy, 22nd Annual Conference
AskBio’s Chief Medical Officer Martin K. (Casey) Childers, DO, PhD at the 22nd Annual Conference of the American Society of Gene & Cell Therapy.
Gene Therapy Panel (Alliance for Regenerative Medicine)
Gene Therapy Panel (Alliance for Regenerative Medicine)
The Growing Promise of Gene Therapy Approaches
The Growing Promise of Gene Therapy Approaches
Media Inquiries
We take pride in our relationships with media representatives. Our scientific experts are always available if needed for interviews and their insights.
Media Contact:
Robin Fastenau, Vice President, Communications
